Everyone Thinks Eli Lilly Is A Weight-Loss Stock. That’s The Trap

Eli Lilly (NYSE:LLY) is having one of those rare market moments where everyone thinks they understand the story. Weight-loss drugs are booming, Novo Nordisk is the obvious rival, prescription data is being watched like playoff scores, and every launch update gets treated like a referendum on the future of obesity medicine. That story is not wrong. It is just incomplete.

Lilly’s real strategy looks less like a one-drug victory lap and more like a layered pharma empire. The first layer is obvious: Mounjaro, Zepbound, and the coming oral obesity pill. The second layer is more interesting: amylin, retatrutide, and combination treatments that may push obesity care beyond today’s GLP-1 debate. The third layer is hiding in plain sight: oncology, including the Ajax Therapeutics acquisition. The fourth layer may be the most disruptive: lower prices, broader Medicare access, and LillyDirect pushing medicine closer to a consumer platform.

So yes, Lilly is a weight-loss stock. But that may be the least interesting version of the story.

The Obvious Story Is Still Very Big

Let’s start with the part everyone already sees. Lilly’s obesity and diabetes franchise is huge, and it is still expanding. Mounjaro and Zepbound have become central to the company’s growth engine. In 2025, Lilly reported revenue growth of 45%, while earnings per share rose 86%. That is not a niche product cycle. That is a full corporate reset.

The runway is still meaningful. Lilly said U.S. obesity market penetration remains only in the mid-single digits. That matters because the category is still early, even after all the headlines, celebrity chatter, and pharmacy shortages. Zepbound also continues to show strong momentum, with a dominant share of new branded obesity prescriptions. That gives Lilly scale, visibility, and negotiating leverage.

The more interesting point is how this growth is happening. LillyDirect now has over one million patients engaging with the platform, and Zepbound self-pay vials represent a large share of new starts. That is unusual for pharma. Patients are not just passively receiving a prescription through the old system. They are acting more like consumers.

That changes the story. Lilly is not only selling medicines. It is learning how to reduce friction, gather patient demand, and build direct relationships. In plain English, Lilly is bringing some consumer-tech muscle into a very old-school industry.

The Next Wave May Not Look Like Today’s GLP-1 Boom

The market likes simple stories. Mounjaro versus Wegovy is a simple story. Injectable versus oral is also simple. But Lilly’s pipeline is starting to make the obesity market look much less simple, in a good way. The company is not just defending today’s franchise. It is already designing the next one.

The key name here is eloralintide, Lilly’s amylin candidate. Amylin works differently from GLP-1 drugs. That gives Lilly another way to target appetite, fullness, and weight loss. More importantly, it may help patients who cannot tolerate today’s incretin drugs or who eventually plateau. That is where the story starts to move beyond “who has the better GLP-1?”

Lilly is also exploring combinations. Pairing eloralintide with tirzepatide could create a more flexible treatment approach. Think of it less like one blockbuster replacing another, and more like stacking tools for different patient needs. Lower doses, better tolerability, and stronger outcomes could matter a lot in the real world.

Then there is retatrutide, Lilly’s triple agonist. In one Phase 3 study, patients with obesity and knee osteoarthritis lost an average of 29% of body weight at 68 weeks. Lilly is also advancing orforglipron, its oral GLP-1, with expected U.S. launch timing in 2026. This is the second layer: Lilly is building a menu, not a single main course.

The Ajax Deal Shows Lilly Is Not Betting Everything On Obesity

Now comes the part that makes this story more interesting. While investors debate obesity prescription trends, Lilly is also buying and building elsewhere. The Ajax Therapeutics deal is a useful signal because it shows management is not treating obesity as the only growth story in the building.

Ajax is developing next-generation therapies for blood cancers, including myelofibrosis and other myeloproliferative neoplasms. Its lead program, AJ1-11095, is a Type II JAK2 inhibitor in Phase 1 development. The deal is worth up to $2.3 billion in cash, including milestone payments. That is not the kind of transaction that changes next quarter’s sales model. It is the kind that tells you how management is thinking.

Lilly appears to be using obesity-driven cash flow to widen the company’s future opportunity set. Oncology already matters to Lilly, with Jaypirca and other programs moving through the pipeline. The earnings call also highlighted broader progress in cancer, immunology, neuroscience, and cardiometabolic health.

That matters because obesity drugs may face pricing pressure over time. Competitors will keep coming. Payers will push back. Governments will negotiate. A company with only one pillar can still grow fast, but it also becomes easier to question. Ajax gives Lilly another layer. Obesity may fund the empire, while oncology and other areas help diversify it.

The Pricing Shift Could Change The Game

Here is where the story gets a little uncomfortable. Lilly’s biggest opportunity may also come with lower prices. That sounds strange, but it may be the new reality. The company is preparing for a world where access and volume matter as much as headline price.

The Medicare agreement is important because eligible patients could access obesity medicines at a $50 monthly out-of-pocket cost. That is a much lower and more predictable price point for many people. Lilly has said this should expand access and increase utilization. It also expects the access change to become effective no later than July 1, 2026.

There is a trade-off. Lilly expects price to be a low-to-mid-teens drag on growth in 2026. That includes the U.S. obesity access agreement, direct-to-patient pricing changes, Medicaid effects, and China reimbursement dynamics. In other words, the company is not pretending price pressure does not exist.

But Lilly’s view is that volume can more than offset lower realized prices over time. Cheaper access brings more patients into the system. More patients create scale. Scale supports manufacturing, direct distribution, and deeper engagement through LillyDirect. This is where Lilly starts to look different from traditional pharma. It is not only chasing premium pricing. It is preparing for a broader, more consumer-like market.

Final Thoughts

Eli Lilly’s story is not as simple as “great obesity drugs, expensive stock.” The company has a powerful GLP-1 franchise, a deeper next-generation obesity pipeline, an expanding consumer access model, and a growing non-obesity portfolio. The Ajax acquisition adds to that wider strategy, showing Lilly is still thinking beyond the most obvious growth engine.

The valuation, however, leaves little room for casual optimism. As of April 27, 2026, Lilly traded at 12.69x LTM EV/revenue, 26.20x LTM EV/EBITDA, 27.86x LTM EV/EBIT, and 37.83x LTM P/E. Those multiples are lower than earlier peaks, but they still price in strong execution. That makes the stock neither obviously cheap nor easy to dismiss. The balanced view is this: Lilly may be building something bigger than a weight-loss franchise, but investors are already paying a serious price to see that empire take shape.

Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.